TANVEX PHARMACEUTICALS

Live / Registered — Registered (as of 25 May 2021)

What this means for you

Registered since 25 May 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §8 declaration of use is due by 25 May 2027, and its filing window is open now).

Record

Serial number
87323903
Registration number
6358664
Mark type
Word mark
Filed
03 Feb 2017
Published for opposition
09 Mar 2021
Registered
25 May 2021
Next maintenance filing
§8 declaration of use, due by 25 May 2027 (grace period to 25 Nov 2027)
Attorney of record
Dyan M. House

Goods and services

  • Class 005 — Pharmaceuticals: Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome; medicinal agent for human use, namely, medicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome; haematogen, namely, blood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome

Owner

Prosecution history

  • 25 May 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
  • 25 May 2021 — REGISTERED-PRINCIPAL REGISTER
  • 09 Mar 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 09 Mar 2021 — PUBLISHED FOR OPPOSITION
  • 17 Feb 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 03 Feb 2021 — CASE RETURNED TO EXAMINATION
  • 04 Jan 2021 — NOTICE OF ALLOWANCE CANCELLED
  • 02 Feb 2021 — ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
  • 04 Jan 2021 — ASSIGNED TO PETITION STAFF
  • 04 Jan 2021 — PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
  • 18 Dec 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 18 Dec 2020 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
  • 18 Dec 2020 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 18 Dec 2020 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 18 Dec 2020 — TEAS PETITION TO AMEND BASIS RECEIVED

View this trademark record on Rightsy